- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04504539
Use of mOPV1 in Routine Immunization in Pakistan. (mOPV1)
Comparison of mOPV1 Schedules for Routine Immunization in Pakistan. A Community Based Randomized Control Trial
Pakistan has uninterrupted circulation of polioviruses and this may threaten the entire global community. Bivalent OPV (bOPV), which protects against types 1 and 3, is used for routine immunization. However, type-3 wild poliovirus is on the verge of eradication, therefore mOPV1 is important to achieve eradication of type-1 poliovirus.
The main rationale of the study is to interrupt WPV1 circulation and stopping the outbreaks of VDPVs with the help of mOPV1 instead of bOPV2 for routine immunization, which contains live poliovirus, and will eventually lead to complete eradication and containment of type 1 WPV, vaccine-related (VDPV) and Sabin polioviruses. This study will provide data to National Immunization Authorities in order to make strategic decisions about their polio vaccination schedules in anticipation of the potential global bOPV2 to mOPV1 switch and will provide data on the proposed responses to type 1 poliovirus outbreaks.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Wild Polio Virus 1 (WPV1) is the only responsible virus for wild polio cases across the globe. The world has successfully eradicated wild poliovirus (PV) 2 and 3. Poliomyelitis eradication has entered its last phase with only three remaining endemic countries, of which Pakistan is one and has highest number of WPV1 cases in 2019. The main stream strategies by the Global Polio Eradication Initiative has made the substantial progress towards the eradication of poliomyelitis ever since the World Health Assembly has sanctioned it as an emerging global Public Health threat. These strategies focus on high-quality immunization activities (routine and supplemental) that target children from birth to age 5 years with oral poliovirus vaccines (OPVs), and maintaining a system for acute flaccid paralysis surveillance.
Pakistan has uninterrupted circulation of polioviruses and this may threaten the entire global community and implies impending failure of goal of global eradication. According to the Polio endgame strategy 2019-2023, Pakistan and Afghanistan are the only countries in which WPV transmissions continues to be reported. The genetic sampling and environmental surveillance have revealed that WPV1 has predominantly persisted in Pakistan and Afghanistan and are closely linked as they constitute one epidemiological block. Bivalent OPV (bOPV), which protect against types 1 and 3, is used for routine immunization. However, type-3 wild poliovirus is on the verge of eradication, therefore mOPV1 is important to achieve eradication of type-1 poliovirus whose appearance has been continually been confirmed by the genetic and environmental samplings.
The main rationale of the study is to interrupt WPV1 circulation and stopping the outbreaks of VDPVs with the help of mOPV1 instead of bOPV2 for routine immunization, which contains live poliovirus, and will eventually lead to complete eradication and containment of type 1 WPV, vaccine-related (VDPV) and Sabin polioviruses. The study rationale is in line with the Goal 1- Eradication of GPEI. This study will provide data to National Immunization Authorities in order to make strategic decisions about their polio vaccination schedules in anticipation of the potential global bOPV2 to mOPV1 switch and will provide data on the proposed responses to type 1 poliovirus outbreaks.
Research Questions and Main Objectives :
Overall Objectives of the study will be:
- To assess the serum immunity against type 1,2 and 3 polioviruses achieved with two different mOPV1 routine immunization schedule (mOPV1+fIPV (fractional dose intradermal IPV); mOPV1+FIPV (full dose intramuscular IPV))
- To compare the serum immunity against type 1,2 and 3 polioviruses achieved with two different mOPV1 routine immunization schedule with bOPV2 routine immunization schedules (mOPV1+fIPV, mOPV1+FIPV with bOPV2+fIPV, bOPV2+FIPV)
- To assess the type 2 response after One full dose IPV with mOPV1 and bOPV2 routine immunization schedule
- To assess the type 2 response after two fractional doses of IPV with mOPV1 and bOPV2 routine immunization schedule
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ali Saleem
- Phone Number: 4718 02134930051
- Email: ali.saleem@aku.edu
Study Locations
-
-
-
Karachi, Pakistan, 74800
- Aga Khan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
born healthy with birth weight 2.0 kg or more, with immediate cry.
- Parents resident of the study areas Not planning to travel away during entire the study period (birth-154 days; birth - 22 weeks) for 3 months at the time of enrolment
- Parent/guardian provides informed consent
Exclusion Criteria:
Refusal of blood testing and cord blood testing
- Receipt of OPV after birth before eligibility screen
- Newborns with certain medical conditions i.e., syndromic infants, neonate with petechial or purpura (contraindication of intramuscular injections)
- A confirmed diagnosis of immunodeficiency disorder in a blood relative will render the newborn ineligible for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: mOPV with FIPV
mOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a single dose of FIPV at 14 weeks of age.
|
mOPV (monovalent oral polio vaccine) is an oral polio vaccines which consists of only attenuated virus of serotypes 1
FIPV (full dose injectable polio vaccine)
fIPV (fractional dose injectable polio vaccine)
|
Experimental: bOPV with FIPV
bOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a single dose of FIPV at 14 weeks of age.
|
FIPV (full dose injectable polio vaccine)
fIPV (fractional dose injectable polio vaccine)
bOPV (bivalent oral polio vaccine) is an oral polio vaccines which consists of attenuated virus of serotypes 1and 3
|
Experimental: mOPV with fIPV
mOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a two doses of fIPV at 6 weeks and 14 weeks of age.
|
mOPV (monovalent oral polio vaccine) is an oral polio vaccines which consists of only attenuated virus of serotypes 1
FIPV (full dose injectable polio vaccine)
fIPV (fractional dose injectable polio vaccine)
|
Experimental: bOPV with fIPV
bOPV vaccine will be given at birth, 6 weeks, 10 weeks and 14 weeks of age along with a two doses of fIPV at 6 weeks and 14 weeks of age.
|
FIPV (full dose injectable polio vaccine)
fIPV (fractional dose injectable polio vaccine)
bOPV (bivalent oral polio vaccine) is an oral polio vaccines which consists of attenuated virus of serotypes 1and 3
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of children with change in antibody titres following vaccination
Time Frame: This will be checked in samples taken at birth, 6 weeks post vaccination, 10 weeks, 14 weeks and 18 weeks of age
|
The number of children who produce antibodies following vaccination of each of the 4 arms
|
This will be checked in samples taken at birth, 6 weeks post vaccination, 10 weeks, 14 weeks and 18 weeks of age
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ali Saleem, Aga Khan University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2020-3284-11191
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Polio Vaccine
-
PATHChristian Medical College, Vellore, India; Ministry of Science and Technology...CompletedImmunity to Oral Rotavirus Vaccine | Immunity to Oral Polio Vaccine | Shedding of Oral Rotavirus VaccineIndia
-
Bilthoven BiologicalsSerum Institute of India Pvt. Ltd.CompletedImmune Response to Oral Polio VaccineBangladesh
-
Bandim Health ProjectStatens Serum Institut; Research Center for Vitamins and VaccinesUnknownMortality | Children | Oral Polio Vaccine | Morbidity | Measles Vaccination | Non-specific/Heterologous Effects of VaccinesGuinea-Bissau
-
Zhejiang Provincial Center for Disease Control...China National Biotec Group Company ltdCompletedVaccine Reaction | PolioChina
-
Bandim Health ProjectActive, not recruitingMortality | COVID | Morbidity | Poliovirus Vaccine, Oral | Non-Specific Effects of VaccinesGuinea-Bissau
-
Stanford UniversityActive, not recruitingVaccine Hesitancy | Vaccine Refusal | Vaccine KnowledgeKenya
-
Instituto Nacional de Saúde, MozambiqueWorld Health OrganizationCompleted
-
Zhejiang Provincial Center for Disease Control...China National Biotec Group Company LimitedCompleted
-
Stanford UniversityBill and Melinda Gates Foundation; Instituto Nacional de Salud Publica, MexicoCompleted
Clinical Trials on mOPV
-
University of ChileBill and Melinda Gates FoundationUnknown
-
University of VermontWorld Health OrganizationActive, not recruiting